NO923252L - Fosfoinositolglykan-peptid med insulinlignende virkning - Google Patents

Fosfoinositolglykan-peptid med insulinlignende virkning

Info

Publication number
NO923252L
NO923252L NO92923252A NO923252A NO923252L NO 923252 L NO923252 L NO 923252L NO 92923252 A NO92923252 A NO 92923252A NO 923252 A NO923252 A NO 923252A NO 923252 L NO923252 L NO 923252L
Authority
NO
Norway
Prior art keywords
insulin effect
phosphoinositol glycan
glycan peptide
insulin
peptide
Prior art date
Application number
NO92923252A
Other languages
English (en)
Other versions
NO923252D0 (no
NO303452B1 (no
Inventor
Guenter Mueller
Dominique Tripier
Stefan Muellner
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO923252D0 publication Critical patent/NO923252D0/no
Publication of NO923252L publication Critical patent/NO923252L/no
Publication of NO303452B1 publication Critical patent/NO303452B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO923252A 1991-08-20 1992-08-19 Fosfoinositolglykan-peptid med insulinlignende virkning, fremgangsmÕte for fremstilling, legemiddel og anvendelse av forbindelsen for fremstilling av et legemiddel NO303452B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4127495 1991-08-20

Publications (3)

Publication Number Publication Date
NO923252D0 NO923252D0 (no) 1992-08-19
NO923252L true NO923252L (no) 1993-02-22
NO303452B1 NO303452B1 (no) 1998-07-13

Family

ID=6438668

Family Applications (1)

Application Number Title Priority Date Filing Date
NO923252A NO303452B1 (no) 1991-08-20 1992-08-19 Fosfoinositolglykan-peptid med insulinlignende virkning, fremgangsmÕte for fremstilling, legemiddel og anvendelse av forbindelsen for fremstilling av et legemiddel

Country Status (22)

Country Link
US (1) US5624903A (no)
EP (1) EP0532915B1 (no)
JP (1) JP3361126B2 (no)
KR (2) KR100264623B1 (no)
AT (1) ATE147407T1 (no)
AU (1) AU656396B2 (no)
CA (1) CA2076424C (no)
CZ (1) CZ290341B6 (no)
DE (1) DE59207835D1 (no)
DK (1) DK0532915T3 (no)
ES (1) ES2096686T3 (no)
FI (1) FI102842B (no)
GR (1) GR3022895T3 (no)
HR (1) HRP940834B1 (no)
HU (1) HU210431B (no)
IL (1) IL102859A (no)
NO (1) NO303452B1 (no)
SG (1) SG46639A1 (no)
SK (1) SK281333B6 (no)
TW (1) TW224104B (no)
YU (1) YU66892A (no)
ZA (1) ZA926232B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE184611T1 (de) * 1991-11-29 1999-10-15 Hoechst Ag Peptide mit insulinartiger wirkung
DK0559064T3 (da) * 1992-02-29 2001-10-08 Aventis Res & Tech Gmbh & Co Komplekser indeholdende glycosyl-phosphatidylinositol-proteiner og cholansyrederivater, fremgangsmåde til deres fremstilling og deres anvendelse
US5652221A (en) * 1994-11-07 1997-07-29 The University Of Virginia Patent Foundation Method of treating defective glucose metabolism using synthetic insulin substances
GB9618934D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in the treatment of diabetes and obesity
GB9618930D0 (en) * 1996-09-11 1996-10-23 Univ London Metal containing carbohydrates from human tissue which regulate lipogenic activity
GB9618929D0 (en) * 1996-09-11 1996-10-23 Univ London Metal containing carbohydrates from human tissue which regulate glycogen metabolism
KR100481746B1 (ko) * 1996-11-28 2005-08-10 훽스트 악티엔게젤샤프트 인슐린-유사작용을갖는이노시톨글리칸및이를포함하는약제학적제제
DE19649350A1 (de) * 1996-11-28 1998-06-04 Hoechst Ag Inositolglykane mit insulinartiger Wirkung
DK1588716T3 (da) 1998-08-06 2011-05-23 Mountain View Pharmaceuticals Peg-uratoxidase-konjugater og anvendelse deraf
CH697081A5 (de) * 2002-01-22 2008-04-30 Andreas F Dr Schaub Zusammensetzung für die Unterstützung der Geburt eines menschlichen Föten.
EP1378517A1 (en) * 2002-07-05 2004-01-07 Aventis Pharma Deutschland GmbH Phosphoinositolglycan (PIG) binding protein from adipocytes
AU2003248927A1 (en) * 2002-07-10 2004-01-23 Massachusetts Institute Of Technology Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
ITMI20030237A1 (it) * 2003-02-11 2004-08-12 Indena Spa Uso della conglutina di lupino per il trattamento del
DE102004054552A1 (de) * 2004-11-11 2006-05-18 Hcb Happy Child Birth Holding Ag Neue Zusammensetzung zur Erleichterung der Humangeburt
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
CZ2007700A3 (cs) 2005-04-11 2008-02-27 Savient Pharmaceuticals, Inc. Variantní forma urátoxidázy a její použití
MX2007012547A (es) 2005-04-11 2008-03-11 Savient Pharmaceuticals Inc Formas variantes de urato oxidasa y uso de las mismas.
CZ2011827A3 (cs) 2009-06-25 2012-09-26 Savient Pharmaceuticals, Inc. Zpusoby a sady pro predpovídání rizika reakce na infuzi a ztráty odezvy zpusobené protilátkami, monitorováním kyseliny mocové v séru behem lécby pegylovanou urikázou
CN102270762B (zh) * 2010-06-03 2014-08-20 清华大学 锂离子电池电极浆料及应用该电极浆料制备的电极片
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4839466A (en) * 1986-04-11 1989-06-13 The Rockefeller University Insulin activity messengers
US4906468A (en) * 1986-04-11 1990-03-06 The Rockefeller University Insulin activity messengers, their antibodies, and thereof

Also Published As

Publication number Publication date
FI102842B1 (fi) 1999-02-26
CZ255392A3 (en) 1993-03-17
FI102842B (fi) 1999-02-26
FI923702A0 (fi) 1992-08-18
DK0532915T3 (da) 1997-07-07
CZ290341B6 (cs) 2002-07-17
SK281333B6 (sk) 2001-02-12
HUT62013A (en) 1993-03-29
GR3022895T3 (en) 1997-06-30
HRP940834A2 (en) 1997-04-30
TW224104B (no) 1994-05-21
ES2096686T3 (es) 1997-03-16
ZA926232B (en) 1993-04-28
HU210431B (en) 1995-04-28
NO923252D0 (no) 1992-08-19
KR930004327A (ko) 1993-03-22
AU2110992A (en) 1993-02-25
JPH05301891A (ja) 1993-11-16
US5624903A (en) 1997-04-29
AU656396B2 (en) 1995-02-02
JP3361126B2 (ja) 2003-01-07
CA2076424A1 (en) 1993-02-21
ATE147407T1 (de) 1997-01-15
CA2076424C (en) 2003-06-03
EP0532915A2 (de) 1993-03-24
SG46639A1 (en) 1998-02-20
YU66892A (sh) 1995-10-24
EP0532915B1 (de) 1997-01-08
KR100264623B1 (ko) 2000-09-01
DE59207835D1 (de) 1997-02-20
HRP940834B1 (en) 2000-08-31
IL102859A (en) 1998-12-27
NO303452B1 (no) 1998-07-13
KR100318706B1 (ko) 2001-12-28
EP0532915A3 (en) 1994-05-18
IL102859A0 (en) 1993-01-31
SK255392A3 (en) 1995-02-08
FI923702A (fi) 1993-02-21

Similar Documents

Publication Publication Date Title
NO923252D0 (no) Fosfoinositolglykan-peptid med insulinlignende virkning
HUT64235A (en) Process for the production of medical prepartives containing by means of peroral introduction of insuline
EP0339237A3 (en) Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them
ATE44649T1 (de) Glykosylierte insulinabkoemmlinge.
HU9301794D0 (en) Medical preparative for treating chronical viral diseases of liver as well qs method for preparing said medicament
GR3025488T3 (en) Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions
PT87523A (pt) Mischkristalle aus insulin und insulinderivaten verfahren zur herstellung dieser mischkristalle diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
FI953525A0 (fi) Kemiskt syntetiseringsfoerfarande foer framstaellning av ett protein eller en polypeptid
FI892185A (fi) Menetelmä terapeuttisesti käyttökelpoisten peptidiyhdisteiden valmistamiseksi
EP0339549A3 (en) Tyr-peptide analogs
AU611113B2 (en) Basically substituted phenylacetonitriles, their preparation and drugs containing these compounds
DE69432124D1 (de) Verwendung eines inositoltriphosphatester, zur herstellung eines medikamentes
EP0193910A3 (en) Synthesis of a derivative of grf and intermediate peptides
EP0363040A3 (en) Herbicides
EP0303463A3 (en) Method to control leukocyte extravasation
EP0260606A3 (en) Medicament for curing neurotic disturbance or disorder comprising sialocylglycerolipid
ES2147519B1 (es) Utilizacion de un compuesto de tipo retinoide para modular in vivo la actividad desacopladora de la proteina ucp2.
HRP940839B1 (en) Short peptides having the effect of insulin
MX9206732A (es) Nuevas proteinas inhibidoras de trombina a partir de sanguijuelas de tierra.
AU1568995A (en) Analogs of thymosin alpha1

Legal Events

Date Code Title Description
MK1K Patent expired